Central Asian Journal of Pediatrics

Central Asian Journal of Pediatrics


Introduction. In most developed countries, prostate cancer takes a leading place among oncological diseases. In different countries frequency of early diagnosis varies. Unfortunately, nowadays in Uzbekistan the frequency of diagnosis of prostate cancer in the late stages prevails over the early. Material and methods. We analyzed the results of 245 primary multifocal prostate core biopsies performed to patients who were examined in RSSPMCU in the period 2016-2019. Patients were divided into two groups: the first group included 203 patients who underwent primary prostate core biopsy; second group - 42 patients, whom performed mp-MRI and evaluated the risk by classification PI-RADS v2 before biopsy. The procedure was performed TRUS guided,under local anesthesia,using lidocaine gel (Cathejel)+periprostatic nerve block with lidocaine). Material for the study was taken with a biopsy gun BIP-high speed multi, needle 18-20 g x 20 cm. from 10-12 areas of the prostate gland, with coverage of the peripheral and apical zones. In 42 patients of the second group, the same method was used to collect cores from 10-12 sites and, in addition from 2 to 6 cores were shot precisely from the zone of interest revealed by mp-MRI. Results. Among 1stgroup of 203 primary biopsies in 145 (71.4%) patients was verified adenocarcinoma. In patient with PSA level up to 30 ng/ml indicator was 58,6%. In the 2-nd group in patients with PSA up to 30ng/ml cancer detecting indicator was 75%. Conclusions. In the early diagnosis of prostate cancer in patients who have PSA level up to 30 ng/ml, without any suspicious according to DRE and TRUS of prostate, mp-MRI should be added to standard diagnostic scheme before primary biopsy.

First Page


Last Page



1.Schroder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90. 2.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5-29. DOI: 10.3322/caac.21254. 3.Herger K.A., Patel D.P., Hanson H.A. et al. Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. Cancer Med 2016;5(1):136-41. DOI: 10.1002/cam4,549. 4.Tao Z.Q., Shi A.M., Wang K.X., Zhang W.D. Epidemiology of prostate cancer: current status. Eur Rev Med PharmacolSci 2015;19(5):805-12. 5.Akaza H. Epidemiology and prevention. Nihon Rinsho 2016;74(1):13-9. 6.Poulsen M.H., Dysager L., Gerke O. et al. Trends in prostate cancer in elderly in Denmark, 1980-2012. ActaOncol 2016;55(suppl 1):74-8. DOI: 10.3109/0284186X.2015.1115120. 7.Okeanov A.E., Moiseev P.I., Levin L.F. Statistikaonkologicheskihzabolevanij v Respublike Belarus' (2004-2013). Minsk:RNPC OMR im. N.N.Aleksandrova, 2014, 382s. 8.Golovachev S.V., Nurgaliev N.S., Kamarli Z.P., Makimbetov E.K. Sostoyanieonkologicheskojpomoshchiiepidemiologiyarakapredstatel'nojzhelezy v central'noaziatskihrespublikah. ZH. Onkourologiya 2016 №3, s.82-86. DOI: 10.17650/1726-9776-2016-12-3-82-86 9. Soloway MS. Do unto others—why I would want anesthesia for my prostate biopsy. Urology. 2003;62:973-975. 10. Emiliozzi P, Scarpone P, DePaula F, et al. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol. 2004;171:197-199. 11. Shandera KC, Thibault GP, Deshon JE Jr. Variability in patient preparation for prostate biopsy among American urologists. Urology. 1998;52:644-646. 12.Viacheslav V. Iremashvili, Alexander K. Chepurov, Konstantin M. Kobaladze,andSafail I. Gamidov. Periprostatic Local Anesthesia With Pudendal Block for Transperineal Ultrasound-guided Prostate Biopsy: A Randomized Trial. UROLOGY 75: 1023–1028, 2010. © 2010 Elsevier Inc. 13.Joseph C. Presti, Jr., M.D.Prostate biopsy: how many cores are enough?Urologic Oncology: Seminars and Original Investigations 21 (2003) 135–140. 14. Cuocolo, R., et al., Prostate MRI technical parameters standardization: A systematic review on adherence to PI-RADSv2 acquisition protocol. Eur J Radiol, 2019. 120: p. 108662. 15. Mussi, T.C., et al., Interobserver agreement of PI-RADS v. 2 lexicon among radiologists with different levels of experience. J Magn Reson Imaging, 2019. 16. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol. 1979 Sep;17(2):159-63 17. Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura T, Murphy GP, Chu TM: Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 1981 Oct;41(10):3874-6. 18. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM: Prostate antigen: a new potential marker for prostatic cancer. Prostate. 1981;2(1):89-96. 19. Mistry K, Cable G. Meta-analysis of prostate specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003; 16:95-101. 20. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004 May 27;350(22):2239-46. 21. Pushkar' D.YU., Govorov A.V., Sidorenkov A.V., i dr. / Rannyayadiagnostikarakapredstatel'nojzhelezy // Metodicheskierekomendacii № 19. - 2015. – S. 20-37. 22. Perdonà S., Bruzzese D., Ferro M., и др. / Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy // Prostate. - 2013. - №73. - С. 227– 35. doi:10.1002/pros.22561 23. Rubcova N.A., Alekseev B.YA., Mamontova I.S. i dr. Vozmozhnosti MRT v diagnostike lokalizovannoj formy rakapredstatel'nojzhelezy. Medicinskaya vizualizaciya 2014;(1):124-6. 24. Hricak H., Choyke P. L., Eberhardt S. C. et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243(1):28–53. 25. Futterer J. J., Heijmink S. W., Spermon J. R. Imaging the male reproductive tract: current trends and future directions. RadiolClin North Am 2008;46(1):133–47. 26. Futterer J. J., Heijmink S. W. Carcinoma, prostate. In: Baert A. L. (ed.) Encyclopedia of diagnostic imaging. Berlin, Heidelberg, New York: Springer-Verlag, 2008. Vol. 1. Pp. 283–7. 27. Burgener F.A., Meyers S.P. et al. Differential diagnosis in magnetic resonance imaging. - Thieme, 2002. 28. A. S. Korobkin, M. A. SHariya, G. A. Voskanyan, A. Z. Vinarov. Mul'tiparametricheskaya magnitno-rezonansnayatomografiya v diagnostike rakapredstatel'nojzhelezy. andrologiyaigenital'naya hirurgiya,2015, №1. S.53-61 (publ. in Russion). 29.Dolgushin B.I., Tyurin I.E., Luk'yanchenko A.B. i dr. Standarty RKT i MRT-issledovanij s vnutrivennymkontrastirovaniem v onkologii. - M.: RAMN im. Blohina, 2011- S.23-27. 30.Röthke M., Blondin D., Schlemmer H-P., идр. / PI-RADS classification: structured reporting for MRI of the prostate // Rofo. - 2013. – T. 185. - С.253–61. doi:10.1055/s-0032-1330270 31. Weinreb J.C., Barentsz J.O., Choyke P.L., идр. / PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2 // Eurpean Urology. - 2016. – T. 69. - №1. - С. 16–40. doi:10.1016/j.eururo. 2015.08.052 32. Barrett T., Turkbey B., Choyke P.L. / PI-RADS version 2: What you need to know? // Clinical Radiology. - 2015. – T. 70. - № 11. - С. 1165–76. doi:10.1016/j.crad.2015.06.093 33. Mcneal J.E. / The Zonal Anatomy of the Prostate // Prostate. - 1981. - T. 2. - №1. – С. 35–49. doi:10.1055/s-2008-1075885 34. Steiger P., Thoeny H.C. / Prostate MRI based on PI-RADS version 2: How we review and report // Cancer Imaging. - 2016. - T.16. - №9. – C. 1-9. doi:10.1186/s40644-016-0068-2



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.